CD274 and non-small cell lung carcinoma: Importantly, TxflSig1 predicted NSCLC response to anti-PD1 therapy at an AUC of 0.8, which was the best among all well-established ICB biomarkers, including CD274, IFNG, and Merck18 (T-cell-inflamed signature) [51] (Figure 3B).